The presence of COVID-19 not only leads to severe pneumonia and associated sequelae but also significantly affects the epidemiology and antimicrobial resistance patterns of other respiratory pathogens (291, 292)
More people discontinued orforglipron during the trial than those who stopped taking semaglutide, too
For insurance purposes, this matters because coverage typically requires the medication to match your diagnosis
doi: 10.1016/j.eprac.2021.04.001 Summary Keywords semaglutide, overweight, obese, meta-analysis, subgroup Citation Zhang R, Hou Q, Li B, Deng L, Yang Y, Li T, Yao X, Yang L, Lin X, Liao Y, Wang L, Liu Y, Tan J, Wan Z and Shuai P (2023) Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials
There were two coprimary composite CV endpoints